Status:

COMPLETED

A Multicenter Assessment of ALD403 in Chronic Migraine

Lead Sponsor:

Alder Biopharmaceuticals, Inc.

Conditions:

Migraine Disorders

Eligibility:

All Genders

18-55 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.

Eligibility Criteria

Inclusion

  • Diagnosis of migraine at ≤ 35 years of age with history of chronic migraine ≥ 1 year
  • During the 28 day screening period, must have ≥ 15 headache days of which ≥ 8 days were assessed as migraine days with at least 5 migraine attacks as recorded in the eDiary
  • Headache eDiary was completed on at least 22 of the 28 days prior to randomization

Exclusion

  • Confounding pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome) or any pain syndrome that requires regular analgesia
  • Psychiatric conditions that are uncontrolled and untreated, including conditions that are not controlled for a minimum of 6 months prior to screening.
  • History or diagnosis of complicated migraine (ICHD-III beta version, 2013), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, migraine with brainstem aura, sporadic and familial hemiplegic migraine
  • Unable to differentiate migraine from other headaches
  • Subject has received botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections in the head, face, or neck within 4 months prior to screening.
  • Have any clinically significant concurrent medical condition
  • Receipt of any monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial)
  • Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway

Key Trial Info

Start Date :

October 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2016

Estimated Enrollment :

665 Patients enrolled

Trial Details

Trial ID

NCT02275117

Start Date

October 1 2014

End Date

November 1 2016

Last Update

April 8 2020

Active Locations (92)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 23 (92 locations)

1

Research Site

Huntsville, Alabama, United States, 35801

2

Research Site

Mobile, Alabama, United States, 36608

3

Research Site

Phoenix, Arizona, United States, 85027

4

Research Site

Scottsdale, Arizona, United States, 85259

A Multicenter Assessment of ALD403 in Chronic Migraine | DecenTrialz